Mansfield C, Ndife B, Chen J, Gallaher K, Ghate S. Patient preferences for treatment of metastatic melanoma. Future Oncol. 2019 Apr;15(11):1255-68. doi: 10.2217/fon-2018-0871

AIM: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments.

A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes.

RESULTS: The 200 survey respondents had distinct preferences. Avoiding a 30% risk of colitis or hormone gland problems and avoiding severe fever were more important to respondents than avoiding a 20% risk of extreme sun sensitivity (P < 0.05). Patients preferred taking pills to receiving intravenous infusions in a clinic. When attributes were combined, approximately 85% of respondents preferred a profile similar to targeted therapy over a profile similar to immunotherapy.

CONCLUSION: Taking patient preferences into account can help patients get the full benefit from metastatic melanoma therapies.

Share on: